Developing vaccines against pandemic influenza.
Identifieur interne : 000428 ( Pmc/Curation ); précédent : 000427; suivant : 000429Developing vaccines against pandemic influenza.
Auteurs : J M WoodSource :
- Philosophical Transactions of the Royal Society of London. Series B [ 0962-8436 ] ; 2001.
Abstract
Pandemic influenza presents special problems for vaccine development. There must be a balance between rapid availability of vaccine and the safeguards to ensure safety, quality and efficacy of vaccine. Vaccine was developed for the pandemics of 1957, 1968, 1977 and for the pandemic alert of 1976. This experience is compared with that gained in developing vaccines for a possible H5N1 pandemic in 1997-1998. Our ability to mass produce influenza vaccines against a pandemic threat was well illustrated by the production of over 150 million doses of 'swine flu' vaccine in the USA within a 3 month period in 1976. However, there is cause for concern that the lead time to begin vaccine production is likely to be about 7-8 months. Attempts to reduce this time should receive urgent attention. Immunogenicity of vaccines in pandemic situations is compared over the period 1968-1998. A consistent feature of the vaccine trials is the demonstration that one conventional 15 microg haemagglutinin dose of vaccine is not sufficiently immunogenic in naive individuals. Much larger doses or two lower doses are needed to induce satisfactory immunity. There is some evidence that whole-virus vaccines are more immunogenic than split or subunit vaccines, but this needs substantiating by further studies. H5 vaccines appeared to be particularly poor immunogens and there is evidence that an adjuvant may be needed. Prospects for improving the development of pandemic vaccines are discussed.
Url:
DOI: 10.1098/rstb.2001.0981
PubMed: 11779397
PubMed Central: 1088574
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000428
Links to Exploration step
PMC:1088574Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Developing vaccines against pandemic influenza.</title>
<author><name sortKey="Wood, J M" sort="Wood, J M" uniqKey="Wood J" first="J M" last="Wood">J M Wood</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">11779397</idno>
<idno type="pmc">1088574</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1088574</idno>
<idno type="RBID">PMC:1088574</idno>
<idno type="doi">10.1098/rstb.2001.0981</idno>
<date when="2001">2001</date>
<idno type="wicri:Area/Pmc/Corpus">000428</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000428</idno>
<idno type="wicri:Area/Pmc/Curation">000428</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000428</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Developing vaccines against pandemic influenza.</title>
<author><name sortKey="Wood, J M" sort="Wood, J M" uniqKey="Wood J" first="J M" last="Wood">J M Wood</name>
</author>
</analytic>
<series><title level="j">Philosophical Transactions of the Royal Society of London. Series B</title>
<idno type="ISSN">0962-8436</idno>
<idno type="eISSN">1471-2970</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Pandemic influenza presents special problems for vaccine development. There must be a balance between rapid availability of vaccine and the safeguards to ensure safety, quality and efficacy of vaccine. Vaccine was developed for the pandemics of 1957, 1968, 1977 and for the pandemic alert of 1976. This experience is compared with that gained in developing vaccines for a possible H5N1 pandemic in 1997-1998. Our ability to mass produce influenza vaccines against a pandemic threat was well illustrated by the production of over 150 million doses of 'swine flu' vaccine in the USA within a 3 month period in 1976. However, there is cause for concern that the lead time to begin vaccine production is likely to be about 7-8 months. Attempts to reduce this time should receive urgent attention. Immunogenicity of vaccines in pandemic situations is compared over the period 1968-1998. A consistent feature of the vaccine trials is the demonstration that one conventional 15 microg haemagglutinin dose of vaccine is not sufficiently immunogenic in naive individuals. Much larger doses or two lower doses are needed to induce satisfactory immunity. There is some evidence that whole-virus vaccines are more immunogenic than split or subunit vaccines, but this needs substantiating by further studies. H5 vaccines appeared to be particularly poor immunogens and there is evidence that an adjuvant may be needed. Prospects for improving the development of pandemic vaccines are discussed.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Philos Trans R Soc Lond B Biol Sci</journal-id>
<journal-title>Philosophical Transactions of the Royal Society of London. Series B</journal-title>
<issn pub-type="ppub">0962-8436</issn>
<issn pub-type="epub">1471-2970</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">11779397</article-id>
<article-id pub-id-type="pmc">1088574</article-id>
<article-id pub-id-type="doi">10.1098/rstb.2001.0981</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Developing vaccines against pandemic influenza.</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Wood</surname>
<given-names>J M</given-names>
</name>
</contrib>
</contrib-group>
<aff>National Institute for Biological Standards and Control, Blanche Lane, Potters Bar, Herts EN6 3QG, UK. jwood@nibsc.ac.uk</aff>
<pub-date pub-type="ppub"><day>29</day>
<month>12</month>
<year>2001</year>
</pub-date>
<volume>356</volume>
<issue>1416</issue>
<fpage>1953</fpage>
<lpage>1960</lpage>
<abstract><p>Pandemic influenza presents special problems for vaccine development. There must be a balance between rapid availability of vaccine and the safeguards to ensure safety, quality and efficacy of vaccine. Vaccine was developed for the pandemics of 1957, 1968, 1977 and for the pandemic alert of 1976. This experience is compared with that gained in developing vaccines for a possible H5N1 pandemic in 1997-1998. Our ability to mass produce influenza vaccines against a pandemic threat was well illustrated by the production of over 150 million doses of 'swine flu' vaccine in the USA within a 3 month period in 1976. However, there is cause for concern that the lead time to begin vaccine production is likely to be about 7-8 months. Attempts to reduce this time should receive urgent attention. Immunogenicity of vaccines in pandemic situations is compared over the period 1968-1998. A consistent feature of the vaccine trials is the demonstration that one conventional 15 microg haemagglutinin dose of vaccine is not sufficiently immunogenic in naive individuals. Much larger doses or two lower doses are needed to induce satisfactory immunity. There is some evidence that whole-virus vaccines are more immunogenic than split or subunit vaccines, but this needs substantiating by further studies. H5 vaccines appeared to be particularly poor immunogens and there is evidence that an adjuvant may be needed. Prospects for improving the development of pandemic vaccines are discussed.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000428 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000428 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:1088574 |texte= Developing vaccines against pandemic influenza. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:11779397" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |